REVENUE RECOGNITION

3 Months Ended

Mar. 29, 2025

Revenue from Contract with Customer [Abstract]

REVENUE RECOGNITION

REVENUE RECOGNITION

The following is a summary of our net sales by category (in millions):

	Three Months Ended
	March 29, 2025		March 30, 2024
CSCA
Upper Respiratory	$	137.9	$	130.3
Nutrition	104.8		90.6
Digestive Health	103.0		122.2
Pain and Sleep-Aids	76.6		82.6
Healthy Lifestyle	70.4		71.3
Oral Care	62.0		64.7
Skin Care	48.6		49.6
Women's Health	15.0		27.2
Vitamins, Minerals, and Supplements ("VMS")	1.6		4.2
Other CSCA(1)	0.8		1.4
Total CSCA	$	620.7	$	644.1
CSCI
Skin Care	$	111.5	$	114.7
Upper Respiratory	73.5		69.1
Healthy Lifestyle	66.6		64.6
Pain and Sleep-Aids	53.6		51.4
VMS	37.7		44.6
Women's Health	32.4		32.0
Oral Care	22.5		28.7
Digestive Health	9.6		9.5
Other CSCI(1)	15.9		23.3
Total CSCI	$	423.1	$	437.9
Total net sales	$	1,043.9	$	1,082.1

(1) Consists primarily of other miscellaneous or otherwise uncategorized product lines, none of which is greater than 10% of the segment net sales.

The following table provides information about contract assets from contracts with customers (in millions):

	Balance Sheet Location	March 29, 2025		December 31, 2024
Short-term contract assets	Prepaid expenses and other current assets	$	38.2	$	43.9

We generated net sales in the following geographic locations(1) (in millions):

	Three Months Ended
	March 29, 2025		March 30, 2024
U.S.	$	609.3	$	632.3
Europe(2)	412.3		419.7
All other countries(3)	22.3		30.1
Total net sales	$	1,043.9	$	1,082.1

(1) The net sales by geography are derived from the location of the entity that sells to a third party.

(2) Includes Ireland net sales of $11.0 million for the three months ended March 29, 2025, and $4.3 million for the three months ended March 30, 2024.

(3) Includes net sales generated primarily in Australia and Canada.